View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 18, 2020

Covid-19 boosts big bio/pharma drug sales but Regeneron may be falling short

By Victoria Smith

The current pandemic has led to temporarily increased drug sales for most influential Bio/Pharma companies in Q1 of this year. Brokers recognise that these sales increase sales when contrasted with those anticipated for Q1 2020 due to Covid-19-related purchases, as individuals stockpiled in preparation for decreased medical access in the lockdown.

Nevertheless, companies with fewer marketed drugs relying predominantly on the Covid-19 asset in their pipeline are gambling on the drug going to market, while other prominent Bio/Pharma companies may prevail in the long-term due to their diverse drug portfolios. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology